Advertisements


Gilead"s remdesivir improves time to recovery for COVID-19 patients in peer-reviewed results, NIAID says

Gilead Sciences Inc.'s antiviral drug remdesivi.....»»

Category: topSource: marketwatchMay 22nd, 2020

Gilead’s remdesivir improves recovery time of coronavirus patients in NIH trial

Gilead’s remdesivir improves recovery time of coronavirus patients in NIH trial.....»»

Category: topSource: washpostApr 29th, 2020

NIH says COVID-19 patients on remdesivir had 31% faster recovery time

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 29th, 2020

Gilead"s shares rise on report of experimental drug"s promise in COVID-19

Shares of Gilead Sciences Inc rose 10% in early trading on Friday after a report that patients with COVID-19 treated with the company's experimental drug, remdesivir, in a clinical trial showed rapid recovery in fever and respiratory symptoms......»»

Category: topSource: reutersApr 17th, 2020

Stocks soar as coronavirus treatment shows promise, Trump targets reopening

A trial conducted by University of Chicago Medicine found the Gilead Sciences drug remdesivir showed promising results in the treatment of patients with COVID-19......»»

Category: topSource: foxnewsApr 17th, 2020

Gilead drug produced ‘rapid’ recovery in coronavirus patients, report says

University of Chicago Medicine researchers said they saw “rapid recoveries” in 125 COVID-19 patients taking Gilead Sciences Inc.’s experimental drug remdesivir as part of a clinical trial, according to Stat News......»»

Category: topSource: marketwatchApr 16th, 2020

How does Gilead market a pandemic treatment?

In a matter of weeks, remdesivir has gone from a shelved, failed hepatitis C treatment to the center of a national effort to treat patients suffering from covid-19, the illness caused by the novel coronavirus......»»

Category: topSource: moneycentralMay 7th, 2020

How does Gilead market a pandemic treatment?

In a matter of weeks, remdesivir has gone from a shelved, failed hepatitis C treatment to the center of a national effort to treat patients suffering from covid-19, the illness caused by the novel coronavirus......»»

Category: topSource: moneycentralMay 7th, 2020

FDA clears Gilead"s Covid-fighting drug remdesivir

A once-failed Gilead Sciences Inc. drug, turned a superstar in the Covid-19 crisis, was given emergency use authorization Friday by federal regulators. Remdesivir, which scored positive results in late-stage clinical trials by Foster City-based Gilead (.....»»

Category: topSource: bizjournalsMay 1st, 2020

FDA grants Gilead’s remdesivir emergency authorization for COVID-19 treatment

The Food and Drug Administration on Friday granted an emergency use authorization to Gilead Sciences Inc.’s remdesivir, a decade-old experimental therapy first tested on Ebola disease patients, as a COVID-19 treatment......»»

Category: topSource: marketwatchMay 1st, 2020

Gilead aims to expand remdesivir output for COVID-19, posts flat 1st-quarter results

Gilead Sciences Inc , maker of the experimental coronavirus drug remdesivir, on Thursday said it will work with international partners to expand production of the potential COVID-19 treatment......»»

Category: topSource: reutersApr 30th, 2020

Gilead aims to expand remdesivir output for COVID-19, posts flat first-quarter results

Gilead Sciences Inc , maker of the experimental coronavirus drug remdesivir, on Thursday reported flat first-quarter earnings and said it with work with international partners to expand production of potential COVID-19 treatment......»»

Category: topSource: reutersApr 30th, 2020

FDA moving at "lightning speed" on Gilead drug

The Food and Drug Administration is moving at “lightning speed” to review data on Gilead Sciences Inc.’s experimental Covid-19 treatment remdesivir, Commissioner Stephen Hahn said, after encouraging results emerged from a key U.S. trial......»»

Category: topSource: moneycentralApr 30th, 2020

FDA moving at "lightning speed" on Gilead drug

The Food and Drug Administration is moving at “lightning speed” to review data on Gilead Sciences Inc.’s experimental Covid-19 treatment remdesivir, Commissioner Stephen Hahn said, after encouraging results emerged from a key U.S. trial......»»

Category: topSource: moneycentralApr 30th, 2020

Trump wants FDA to move "quickly" on remdesivir approval

The Food and Drug Administration has been in "sustained and ongoing" discussions with Gilead Sciences to make antiviral drug remdesivir available to Covid-19 patients "as quickly as possible, as appropriate," the agency said......»»

Category: topSource: moneycentralApr 29th, 2020

Gilead says NIAID study of remdesivir as COVID-19 treatment met primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 29th, 2020

Gilead says NIAID study of remdesivir as COVID-19 treatment met primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 29th, 2020

Gilead"s remdesivir may still work in moderate COVID patients, says SunTrust

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 23rd, 2020

Gilead stock tumbles after Stat report on weak data in remdesivir trial in China

Shares of Gilead Sciences Inc. were down 5.3% in trading on Thursday after a Stat News report said a draft of the clinical trial results for remdesivir, an experimental drug being tested as a treatment for COVID-19, showed that the drug did not spe.....»»

Category: topSource: marketwatchApr 23rd, 2020

Stocks sink as Gilead Sciences" remdesivir said to show disappointing results: all benchmarks briefly negative

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 23rd, 2020

Gilead increases enrollment target for remdesivir trial in COVID-19 patients

Gilead Sciences Inc on Friday increased enrollment target by 3,600 for a trial testing its experimental drug, remdesivir, in severe COVID-19 patients, a day after a media report said the drug was showing promise......»»

Category: topSource: reutersApr 17th, 2020